BIIB vs GILD
Biogen Inc. and Gilead Sciences, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | BIIB | GILD |
|---|---|---|
| Revenue | $9.9B | $29.4B |
| Net income | $1.3B | $8.5B |
| Gross margin | 75.7% | 78.8% |
| Net margin | 13.1% | 28.9% |
| Return on equity | 11.0% | 40.5% |
| Diluted EPS | $8.79 | $6.78 |
| Dividend / share | — | $3.16 |
| Payout ratio | — | 47.0% |
| Free cash flow | $2.1B | $9.5B |
| Equity | $14.8B | $22.7B |
| Net debt / equity | 0.41× | 0.77× |
| Current ratio | 2.68× | 1.55× |
| Revenue CAGR 5y | −6.0% | 3.6% |
| Profit CAGR 5y | −20.2% | 133.3% |
GILD bills 3.0× the revenue of BIIB, and keeps more of each dollar of revenue as profit (28.9% against 13.1%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | BIIB | GILD |
|---|---|---|
| FY2025 | $9.9B | $29.4B |
| FY2024 | $9.7B | $28.8B |
| FY2023 | $9.8B | $27.1B |
| FY2022 | $10.2B | $27.3B |
| FY2021 | $11.0B | $27.3B |
| FY2020 | $13.4B | $24.7B |
| FY2019 | $14.4B | $22.4B |
| FY2018 | $13.5B | $22.1B |
| FY2017 | $12.3B | $26.1B |
| FY2016 | $11.4B | $30.4B |
Net income by year
Bottom line
| Fiscal year | BIIB | GILD |
|---|---|---|
| FY2025 | $1.3B | $8.5B |
| FY2024 | $1.6B | $480.0M |
| FY2023 | $1.2B | $5.7B |
| FY2022 | $3.0B | $4.6B |
| FY2021 | $1.6B | $6.2B |
| FY2020 | $4.0B | $123.0M |
| FY2019 | $5.9B | $5.4B |
| FY2018 | $4.4B | $5.5B |
| FY2017 | $2.5B | $4.6B |
| FY2016 | $3.7B | $13.5B |
Advertisement
AdSense · Rectangle 336×280
More in this industry